×
Concentras Parent Price to Free Cash Flow Ratio 2022-2024 | CON
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Concentras Parent price to free cash flow ratio from 2022 to 2024. Price to free cash flow ratio can be defined as
View More
Concentras Parent Price to Free Cash Flow Ratio 2022-2024 | CON
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Concentras Parent price to free cash flow ratio from 2022 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company Name
Market
Cap
Elevance Health (ELV)
$91.4B
Cencora (COR)
$47.5B
DiDi Global (DIDIY)
$23.3B
Natera (NTRA)
$21.4B
ICON (ICLR)
$16.1B
Viatris (VTRS)
$15.6B
Avantor (AVTR)
$13.4B
Revvity (RVTY)
$13.4B
CochLear (CHEOY)
$12.8B
BioMerieux (BMXMF)
$12.7B
Solventum (SOLV)
$11.6B
Medpace Holdings (MEDP)
$9.8B
Doximity (DOCS)
$9.6B
Charles River Laboratories (CRL)
$9.5B
HealthEquity (HQY)
$9B
Sonic Healthcare (SKHHY)
$8.8B
Bausch + Lomb (BLCO)
$6.9B
Life Times (LTH)
$5.1B
Sotera Health (SHC)
$3.9B
Organon (OGN)
$3.8B
BrightSpring Health Services (BTSG)
$3.2B
Surgery Partners (SGRY)
$2.9B
PACS (PACS)
$2.6B
Ardent Health Partners (ARDT)
$2.4B
Premier (PINC)
$2.1B
Alignment Healthcare (ALHC)
$2.1B
Ryman Healthcare (RYHTY)
$2B
GeneDx Holdings (WGS)
$2B
GoodRx Holdings (GDRX)
$1.6B
Teladoc Health (TDOC)
$1.5B